Publication: Aberrant Expression of c-Met and HGF/c-Met Pathway Provides Survival Advantage in B-Chronic Lymphocytic Leukemia
| dc.contributor.authors | Eksioglu-Demiralp, Emel; Akdeniz, Tuba; Bayik, Mahmut | |
| dc.date.accessioned | 2022-03-14T10:06:05Z | |
| dc.date.accessioned | 2026-01-10T18:36:00Z | |
| dc.date.available | 2022-03-14T10:06:05Z | |
| dc.date.issued | 2011-01 | |
| dc.description.abstract | Background: B-chronic lymphocytic leukemia (B-CLL) is characterized by accumulation of CD5(+) B lymphocytes. Decreased VLA-4 (Cd49d/CD29) and CD11a expression and defective adhesion in B-CLL have been previously shown, although there was no substantial data about its importance in immunobiology of B-CLL. The hepatocyte growth factor (HGF) receptor, c-met, plays a role in adhesion by acting on VLA-4. c-met and VLA-4 share crucial signaling molecules in cell survival. In this study, relationship between expressions of c-met and CD49d, CD11a, and additional common signaling molecules in B-CLL was investigated. Methods: White blood cells from 24 patients with CLL were studied by flow cytometry and/or western blotting prior to and after culturing with recombinant HGF. HGF level from sera was measured with a bead-based flow cytometric assay. Results: c-met alpha and c-met beta were expressed on B-CLL cells, while no expression was observed on normal donor CD19+ cells. This increase was inversely correlated with decreased expression of adhesion molecules. Serum level of HGF in B-CLL was found to be increased. In vitro experiments showed that HGF supported survival in B-CLL cells supporting the possible function of HGF/c-met pathway in B-CLL. Furthermore, expressions of critical signaling molecules shared by both VLA-4 and HGF/c-met systems including Bcl-XL, Akt, PI3K, and phospho-bad(136) following HGF stimulations of B-CLL cells have been found to be increased. Conclusion: Increased expression of c-met and HGF may bypass the importance of expression of critical adhesion molecules and support survival of B-CLL cells. c-met, being one of the surface tyrosine kinases, may serve as a target for future therapies in B-CLL meriting more attention. (C) 2010 International Clinical Cytometry Society | |
| dc.identifier.doi | 10.1002/cyto.b.20553 | |
| dc.identifier.issn | 1552-4949 | |
| dc.identifier.pubmed | 20809501 | |
| dc.identifier.uri | https://hdl.handle.net/11424/244042 | |
| dc.identifier.wos | WOS:000285981000001 | |
| dc.language.iso | eng | |
| dc.publisher | WILEY-LISS | |
| dc.relation.ispartof | CYTOMETRY PART B-CLINICAL CYTOMETRY | |
| dc.rights | info:eu-repo/semantics/openAccess | |
| dc.subject | B-CLL | |
| dc.subject | CD49d | |
| dc.subject | c-met alpha | |
| dc.subject | c-met beta | |
| dc.subject | HGF | |
| dc.subject | flow cytometry | |
| dc.subject | bead-based cytometric assays | |
| dc.subject | HEPATOCYTE GROWTH-FACTOR | |
| dc.subject | MARROW STROMAL CELLS | |
| dc.subject | SIGNAL-TRANSDUCTION | |
| dc.subject | ADHESION MOLECULES | |
| dc.subject | ANTIGEN RECEPTOR | |
| dc.subject | PROGENITOR CELLS | |
| dc.subject | ACTIVATION | |
| dc.subject | APOPTOSIS | |
| dc.subject | KINASE | |
| dc.subject | VLA-4 | |
| dc.title | Aberrant Expression of c-Met and HGF/c-Met Pathway Provides Survival Advantage in B-Chronic Lymphocytic Leukemia | |
| dc.type | article | |
| dspace.entity.type | Publication | |
| oaire.citation.endPage | 7 | |
| oaire.citation.issue | 1 | |
| oaire.citation.startPage | 1 | |
| oaire.citation.title | CYTOMETRY PART B-CLINICAL CYTOMETRY | |
| oaire.citation.volume | 80B |
Files
Original bundle
1 - 1 of 1
